Progyny (PGNY) investor relations material

Business momentum and market trends

• Pipeline and deal size are both stronger than the prior year, with early client commitments and increased RFP activity indicating robust demand.

• Industry growth is driven by macro trends such as declining fertility rates and delayed family building, with the fertility market growing at a 9–10% CAGR.

• 99% client retention and positive client outcomes, including improved pregnancy rates and reduced NICU stays, reinforce value proposition.

• Health plan partnerships, such as with Cigna and regional Blues, are deepening and expected to add incremental value and lives.

• Two largest clients up for renewal have already committed to stay, with discussions underway for expanded product offerings.

Product and distribution expansion

• Progyny Select targets small businesses, with distribution partners signed and meaningful pull-through expected in late Q4.

• No direct standalone supplemental plan competition for Progyny Select outside of mandated states.

• New products in menopause, postpartum, leave, and benefit navigation are resonating, with 20% of current and 40% of new clients adding these benefits.

• Investments in digital assets and global product suite aim to match U.S. offerings for multinational clients.

Utilization, guidance, and financial strategy

• Utilization rates remain consistent and at the higher end of guidance, supporting a strong outlook for the year.

• Guidance philosophy incorporates current trends and allows for variability, with current activity skewing toward the high end.

• Platform investments focus on efficiency, interoperability, and AI to enhance care management and member experience.

• ROI strategy centers on empowering care advocates and avoiding future hiring as the business scales.

• M&A remains focused on small, accretive tuck-in deals; excess cash may be returned to shareholders via buybacks.